Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Hold” Rating from Maxim Group

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “hold” rating reaffirmed by research analysts at Maxim Group in a research report issued on Wednesday,Benzinga reports.

Several other equities analysts have also weighed in on the stock. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, March 14th. Chardan Capital restated a “buy” rating and set a $40.00 price objective on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. Finally, D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Reviva Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $66.67.

Reviva Pharmaceuticals Trading Up 4.1%

NASDAQ:RVPH opened at $0.82 on Wednesday. Reviva Pharmaceuticals has a twelve month low of $0.59 and a twelve month high of $23.20. The company has a 50-day moving average of $3.45 and a 200-day moving average of $7.53. The firm has a market cap of $10.44 million, a price-to-earnings ratio of -0.09 and a beta of 0.64.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RVPH. Armistice Capital LLC acquired a new position in shares of Reviva Pharmaceuticals in the second quarter worth about $1,026,000. 683 Capital Management LLC acquired a new position in shares of Reviva Pharmaceuticals in the second quarter worth about $381,000. Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 87.6% in the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after buying an additional 489,711 shares during the period. State Street Corp boosted its holdings in shares of Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.